FIGURE 1.

Patient disposition (AMARANTH and DAYBREAK‐ALZ).

*Number of patients with baseline scan and analyzable post‐baseline scan. ^†Patients could participate in the flortaucipir PET or FDG PET imaging substudy (not both) and could also participate in the longitudinal florbetapir PET imaging substudy. Note: percentages are proportion of randomized patients, unless otherwise noted. Abbreviations: CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography